The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: An observational study

BMC Neurology

Volumn 11, Issue , 2011, Pages

  Beer, Karsten ^a   Müller, Martin ^b   Hew Winzeler, Anna M ^c   Bont, Adriano ^d   Maire, Philippe ^e   You, Xiaojun ^f   Foulds, Pamela ^f   Mårlind, Jessica ^g   Curtius, Daniela ^g  

^a Obere Bahnhofstrasse ^*  (Switzerland)

^b LUZERNER KANTONSSPITAL   (Switzerland)

^c Private Practice   (Switzerland)

^d Private Practice   (Switzerland)

^e KLINIK HIRSLANDEN   (Switzerland)

^f BIOGEN   (United States)

^g Biogen Idec International GmbH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1 INTERFERON; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; BETA INTERFERON; IMMUNOLOGIC FACTOR; PEPTIDE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; INJECTION SITE REACTION; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NECROSIS; PATIENT COMPLIANCE; PREVALENCE; SKIN EXAMINATION; SWITZERLAND; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; STATISTICS; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIPLE SCLEROSIS; PEPTIDES; PREVALENCE;

EID: 81055124138     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-11-144     Document Type: Article

References (8)

1. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, Monaghan E, Li D, Weinshenker B, . EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group; University of British Columbia MS/MRI Research Group Randomized, comparative study of interferon β-1a treatment regimens in MS: the EVIDENCE trial. Neurology 2002, 59(10):1496-1506. EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group; University of British Columbia MS/MRI Research Group.
2. Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, Montanari E, Zaffaroni M, . Independent Comparison of Interferon (INCOMIN) Trial Study Group Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002, 359(9316):1453-1460. 10.1016/S0140-6736(02)08430-1, 11988242, Independent Comparison of Interferon (INCOMIN) Trial Study Group.
3. Milanese C, La Mantia L, Palumbo R, Martinelli V, Murialdo A, Zaffaroni M, Caputo D, Capra R, Bergamaschi R, . the North Italy Multiple Sclerosis Group A post-marketing study on interferon β 1b and 1a treatment in relapse-remitting multiple sclerosis: different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry 2003, 74:1689-1692. 10.1136/jnnp.74.12.1689, 1757434, 14638892, the North Italy Multiple Sclerosis Group.
4. O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Christian Kraus C, Sandbrink R, Pohl C, Bogumil T, . for the BEYOND Study Group 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomized, multicentre study. Lancet Neurol 2009, 8(10):889-897. 10.1016/S1474-4422(09)70226-1, 19729344, for the BEYOND Study Group.
5. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003, 61(4):551-554.
6. O'Rourke K, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005, 11(1):46-50. 10.1191/1352458505ms1131oa, 15732266.
7. Girouard N, Théorêt G. Management strategies for improving the tolerability of interferons in the treatment of multiple sclerosis. Can J Neurosci Nurs 2008, 30(4):18-25.
8. Rio J, Porcel J, Tellez N, Sánchez-Betancourt A, Tintoré M, Arévalo MJ, Nos C, Montalban X. Factors related with treatment adherence to interferon β and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005, 11(3):306-309. 10.1191/1352458505ms1173oa, 15957512.